Table 2.
Phenotypic profile of total pMo/Mφ and CD14/CD16 subsets compared to blood of healthy humans.
| Markers | Total CD14+ cells | CD14/CD16 expression subsets | ||||||
|---|---|---|---|---|---|---|---|---|
| Blood | Peritoneum | Blood monocytes | pMo/Mφ | |||||
| CD14++CD16− | CD14++CD16+ | CD14+/lowCD16+ | CD14++CD16− | CD14++CD16+ | CD14highCD16high | |||
| CD11b+ | 86.6 ± 3.1 | 92.4 ± 2.4 | 87.6 ± 3.6 | 77.9 ± 4.2 | 51.5 ± 7.3 | 77.9 ± 5.1 | 97.0 ± 1.3** | 99.2 ± 0.5 |
| CD11c+ | 8.6 ± 1.7 | 89.2 ± 4.5*** | 6.6 ± 1.5 | 24.3 ± 4.7 | 27.1 ± 6.0 | 77.2 ± 5.2*** | 91.5 ± 2.6*** | 95.1 ± 3.0 |
| CD40+ | 1.8 ± 0.4 | 43.4 ± 7.3*** | 1.8 ± 0.5 | 2.3 ± 0.6 | 4.0 ± 2.1 | 21.2 ± 4.9*** | 60.7 ± 8.2*** | 87.7 ± 6.2 |
| CD62L+ | 75.9 ± 3.7 | 27.4 ± 5.1*** | 81.9 ± 4.1 | 48.8 ± 4.5 | 25.5 ± 5.4 | 11.7 ± 2.6*** | 29.4 ± 5.7** | 66.4 ± 8.9 |
| CD64+ | 82.4 ± 3.5 | 90.4 ± 3.1 | 94.4 ± 1.9 | 63.4 ± 3.5 | 19.2 ± 3.1 | 84.7 ± 1.7*** | 97.2 ± 0.5*** | 99.4 ± 0.2 |
| CD80+ | 3.4 ± 0.7 | 33.7 ± 6.0*** | 7.0 ± 4.0 | 4.0 ± 1.0 | 4.8 ± 1.8 | 9.8 ± 3.4 | 36.9 ± 7.5*** | 78.6 ± 7.5 |
| CD86+ | 74.9 ± 3.8 | 76.0 ± 4.7 | 71.9 ± 5.0 | 89.6 ± 2.4 | 91.0 ± 5.1 | 56.2 ± 5.8* | 95.9 ± 1.3* | 98.9 ± 0.6 |
| CD116+ | 91.2 ± 1.2 | 94.7 ± 1.3* | 95.7 ± 0.7 | 70.4 ± 4.6 | 41.2 ± 4.4 | 89.1 ± 2.2** | 98.8 ± 0.4*** | 99.8 ± 0.1 |
| CD119+ | 79.2 ± 3.7 | 89.7 ± 4.0* | 77.4 ± 3.9 | 90.8 ± 1.6 | 91.4 ± 1.3 | 81.6 ± 5.0 | 97.9 ± 1.3* | 99.3 ± 0.5 |
| CD206+ | 5.2 ± 1.5 | 47.6 ± 7.2*** | 4.7 ± 1.3 | 11.6 ± 3.0 | 11.0 ± 4.3 | 28.2 ± 6.6*** | 60.3 ± 6.1*** | 92.8 ± 1.4 |
| HLA-DR+ | 79.2 ± 6.9 | 88.0 ± 4.2** | 77.2 ± 7.4 | 92.8 ± 2.2 | 96.3 ± 0.8 | 81.2 ± 4.8* | 97.7 ± 1.1** | 97.5 ± 1.8 |
| Slan+ | 1.7 ± 0.5 | 7.0 ± 1.0*** | 0.7 ± 0.4 | 3.4 ± 0.9 | 11.9 ± 2.7 | 2.8 ± 0.6** | 7.5 ± 1.1** | 12.8 ± 1.9 |
Data represent the Mean ± SEM percentage of positive cells for every membrane marker analyzed. *p < 0.05, **p < 0.01, and ***p < 0.001 between percentages of positive pMo/Mφ CD14++CD16− and CD14++CD16+ cells compared to their blood equivalent subsets.